Alcatel-Lucent Enterprise Hosts First Global Virtual Conference for Partners
Alcatel-Lucent Enterprise , a leading digital-age networking, communications and cloud solutions provider, is hosting its Connex21 global partner conference virtually between February 1-4, 2021. It is the latest in an extensive program of virtual events, after the company adapted its priorities to keep employees safe and maintain business continuity for partners and customers.
Over 2,100 Alcatel-Lucent Enterprise partners and industry analysts from all over the world have registered to attend the summit. Under the theme ‘Build 2 Last’, Connex21 will feature speakers including CEO Jack Chen and Rukmini Glanard, Executive Vice President Global Sales, Services and Marketing.
Jack and Rukmini will join other Alcatel-Lucent Enterprise business leaders to outline the company’s 2021 strategy, discuss core business objectives, explain the product roadmap, and explore the growth opportunities this year poses for the business and its international partners.
“Last year was very difficult for every one of us,” comments Jack Chen, CEO of Alcatel-Lucent Enterprise. “The current situation has changed the way we work, and some of these changes will become permanent. This crisis has highlighted the critical need for digital transformation. Digital technology is enabling businesses to generate revenue, retain staff, and survive in challenging conditions. Technology is helping us all to adapt and find ways to grow.”
Over the course of Connex21, executives at the company will host dedicated sessions to demonstrate the impact its innovations are having in vertical industries across the globe. Product specialists will present the Alcatel-Lucent Enterprise roadmap for new solutions designed to support partners in solving business issues and driving growth for customers. The business will also outline its plan to support its partner community in 2021 with Cloud, Network and Communications solutions designed for critical verticals such as Transportation, Healthcare, Education, Government and Hospitality.
“Alcatel-Lucent Enterprise has a long history of evolving with the times,” says Jack Chen. “We’ve had to adapt to address the needs of the enterprise successfully for over 100 years. Versatility is in our DNA and originates from our ability to embrace innovation. Our solutions help businesses grow, irrespective of the market conditions. Our partners believe in our vision to help organisations grow through innovation and, together, we work tirelessly to achieve it. We want to continue to build great relationships and solutions that will last long into the future.”
Alcatel-Lucent Enterprise has a strong ecosystem of 2,900 direct business partners all over the world. This helps the company achieve an effective international reach, with a local focus, for over 830,000 customers in 100 countries around the world.
About Alcatel-Lucent Enterprise
Alcatel-Lucent Enterprise delivers the customised technology experiences enterprises need to make everything connect.
ALE provides digital-age networking, communications and cloud solutions tailored to ensure customers’ success, with flexible business models in the cloud, on premises, and hybrid. All solutions have built-in security and limited environmental impact.
Over 100 years of innovation have made Alcatel-Lucent Enterprise a trusted advisor to more than 830,000 customers in 100 countries around the world.
The privately-owned company with headquarters in France has over 2,900 direct business partners worldwide, achieving an effective global reach with a local focus.
For more information: www.al-enterprise.com .
LinkedIn , Facebook , Twitter , Instagram .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005157/en/
Contact information
UK Press
Lisa McGauley
lisa@fox.agency
Global Press
Carine Bowen
press@al-enterprise.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom